Background: Spasmodic dysphonia is a neurological voice disorder characterized by involuntary adductor (towards midline) or abductor (away from midline) vocal fold spasms during phonation which result in phonatory breaks. Botulinum toxin is currently the gold standard of treatment.
Objective: To determine the efficacy of botulinum toxin therapy for the treatment of spasmodic dysphonia.
Design: Systematic Cochrane review.
Search strategy: The search strategy for this review complied with Cochrane standards. We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (1966 to February 2005), EMBASE (1974 to February 2005), CINAHL (through February 2005), Dissertation Abstracts International (1975 to February 2005) and PsycINFO (1975 to February 2005). The search engine FirstSearch was also used (February 2005). Reference lists for all the obtained studies and other review articles were examined for additional studies.
Selection criteria: All randomized control trials where the participants were randomly allocated prior to intervention and in which botulinum toxin was compared to an alternative treatment, placebo or non-treated control group were included.
Data collection and analysis: Two reviewers independently evaluated all potential studies meeting the selection criteria noted above for inclusion.
Main results: Only one study in the literature met the inclusion criteria. This was the only study identified which reported a treatment/no treatment comparison. It reported significant beneficial effects for fundamental frequency (Fo), Fo range, spectrographic analysis, independent ratings of voice severity and patient ratings of voice improvement.
Reviewer's conclusions: The evidence from randomized controlled trials supporting the effectiveness of botulinum toxin for management of spasmodic dysphonia is deficient. The lack of supporting evidence from randomized controlled trials results in an inability to draw unbiased generalized conclusions regarding the effectiveness of botulinum toxin for all types of spasmodic dysphonia.
Get full access to this article
View all access options for this article.
References
1.
1 Aronson A. Clinical voice disorders: an interdisciplinary approach. Thieme, 1990.
2.
2 Cannito M, Johson P. Spastic dysphonia: a continuum disorder. J Commun Disord1981; 14: 215–223.
3.
3 Blitzer A, Brin MF. Laryngeal dystonia: a series with botulinum toxin therapy. Ann Otol Rhino Laryngol1991; 100: 85–89.
4.
4 Whurr R, Lorch M, Fontana H, Brookes G, Lees A, Marsden CD. The use of botulinum toxin in the treatment of adductor spasmodic dysphonia. J Neurol Neurosurg Psychiatry1993; 56: 526–530.
5.
5 Brin M, Blitzer A, Stewart C. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12 year experience in more than 900 patients. Laryngoscope1998; 98: 193–197.
6.
6 Blitzer A, Sulica L. Botulinum toxin: basic science and clinical uses in otolaryngology. Laryngoscope2001; 111: 218–226.
7.
7 Boone D, McFarlane S. The voice and voice therapy. Allyn & Bacon, 2000.
8.
8 Stemple J. Voice therapy: clinical studies. Singular, 2000.
9.
9 Murry T, Woodson GE. Combined-modality treatment of adductor spasmodic dysphonia with botulinum toxin and voice therapy. J Voice1995; 9: 460–465.
10.
10 Cannito M. Neurological aspects of spasmodic dysphonia. In Vogel D, Cannito M eds. Treating disordered speech motor control. Pro-Ed, 2001.
11.
11 Bielamowicz S, Bidus K, Squire S, Ludlow CL. Assessment of posterior cricoarytenoid botulinum toxin injections in patients with abductor spasmodic dysphonia. Ann Otol Rhinol Laryngol 2001; 110: 406–412.
12.
12 Langeveld TP, Edgar HH, Jeroen JB, Van Rossum M, Zwinderman AH, Baatenburg RJ. Evaluation of voice quality in adductor spasmodic dysphonia before and after botulinum toxin treatment. Ann Otol Rhinol Laryngol2001; 110: 627–634.
13.
13 Adams SG, Hunt EJ, Irish JC et al. Comparison of botulinum toxin injection procedures in adductor spasmodic dysphonia. J Otolaryngol1995; 24:345–351.
14.
14 Bielamowicz S, Ludlow CL. Effects of botulinum toxin on pathophysiology in spasmodic dysphonia. Ann Otol, Rhinol Laryngol2000; 109: 194–203.
15.
15 Rhew K, Fiedler DA, Ludlow CL. Technique for injection of botulinum toxin through the flexible nasolaryngoscope. Otolaryngol Head Neck Surg1994; 111: 787–794.
16.
16 Adams SG, Hunt EJ, Charles DA, Lang AE. Unilateral versus bilateral botulinum toxin injections in spasmodic dysphonia: acoustic and perceptual results. J Otolaryngol1993; 22: 171–175.
17.
17 Bielamowicz S, Sheila SV, Badillo A, Godlewski A. Unilateral versus bilateral injections of botulinum toxin in patients with adductor spasmodic dysphonia. J Voice2002; 16: 117–123.
18.
18 Drost HA, Baatenburg de Jong RJ. Unilateral versus bilateral botulinum toxin injections in adductor spasmodic dysphonia. Ann Otol Rhinol Laryngol1998; 107: 280–284.
19.
19 Green DC, Ward PH, Berke GS, Gerratt BR. Point-touch technique of botulinum toxin injection for the treatment of spasmodic dysphonia. Ann Otol Rhinol Laryngol1992; 101: 883–887.
20.
20 Ford CN, Bless DM, Lowery JD. Indirect laryngoscopic approach for injection of botulinum toxin in spasmodic dysphonia. Otolaryngol Head Neck Surg1990; 103: 752–758.
21.
21 Ludlow CL, Bagley J, Yin SG, Koda J. A comparison of injection techniques using botulinum toxin injection for treatment of the spasmodic dysphonia. J Voice1992; 6: 380–386.
22.
22 Blitzer A, Brin MF, Stewart CF. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope1998; 108: 1435–1441.
23.
23 Ford CN, Bless DM, Patel NY. Botulinum toxin treatment of spasmodic dysphonia: techniques, indications, efficacy. J Voice1992; 6: 370–376.
24.
24 Lundy DS, Ling Lu F, Casiano RR, Xue JW. The effect of patient factors on response outcomes to botox treatment for spasmodic dysphonia. J Voice1998; 4: 460–466.
25.
25 Schonweiler R, Wohlfarth K, Dengler R, Ptok M. Supraglottal injection of botulinum toxin type A in adductor spasmodic dysphonia with both intrinsic and extrinsic hyperfunction. Laryngoscope1998; 108: 55–63.
26.
26 Zwirner P, Murry T, Swenson M, Woodson GE. Acoustic changes in spasmodic dysphonia after botulinum toxin injection. J Voice1991; 5: 78–84.
27.
27 Sapienza CM, Cannito MP, Murry T, Branski R, Woodson G. Acoustic variations in reading produced by speakers with spasmodic dysphonia pre-botox injection and within early stages of post-botox injection. J Speech Hear Res2002; 45: 830–843.
28.
28 Fisher KV, Scherer RC, Swank PR, Giddens CG, Patten D. Electroglottographic tracking of phonatory response to Botox. J Voice1999; 13: 203–209.
29.
29 Rodriguez AA, Ford CN, Bless DM, Harmon RL. Electromyographic assessment of spasmodic dysphonia patients prior to botulinum toxin injection. Electromyogr Clin Neurophysiol1994; 34: 403–407.
30.
30 Mehta RP, Goldman SN, Orloff LA. Long-term therapy for spasmodic-dysphonia: acoustic and aerodynamic outcomes. Arch Otolaryngol Head Neck Surg2001; 127: 393–399.
31.
31 Wong DLH, Irish JC, Adams SG, Durkin LC, Hunt EJ. Laryngeal image analysis following botulinum toxin injections in spasmodic dysphonia. J Otolaryngol1995; 24: 64–68.
32.
32 Papathanasiou I, MacDonald L, Whurr R, Brookes G, Jahanshahi M. Perceived stigma among patients with spasmodic dysphonia. J Med Speech Lang Pathol1997; 5: 251–261.
33.
33 Whurr R, Lorch M, Lindsay M, Brookes G, Marsden C. Psychological function in spasmodic dysphonia before and after treatment with botulinum toxin. J Med Speech Lang Pathol1998; 2: 81–91.
34.
34 Whurr R, Lorch M, Nye C. The treatment of spasmodic dysphonia with botulinum toxin. Neurol Rev Int1997; 2: 11–15.
35.
35 Duffy J, Yorkston K. Medical interventions for spasmodic dysphonia and some related conditions: a systematic review. J Med Speech Lang Pathol2003; 11:ix–lviii.
36.
36 Boutsen F, Cannito M, Taylor M, Bender B. Botox treatment for adductor spasmodic dysphonia: a meta-analysis. J Speech Lang Hear Res2002; 45: 469–481.
37.
37 Watts CR, Whurr R, Nye C. Botulinum toxin injections for the treatment of spasmodic dysphonia (Cochrane Review). The Cochrane Library, Issue 3. John Wiley & Sons, 2004.
38.
38 Wong DL, Adams SG, Irish JC, Durkin LC, Hunt EJ, Charlton MP. Effect of neuromuscular activity on the response to botulinum toxin injections in spasmodic dysphonia. J Otolaryngol1995; 24:209–216.
39.
39 Finnegan E, Luschei E, Gordon J, Barkmeier J, Hoffman H. Increased stability of airflow following botulinum toxin injection. Laryngoscope1999; 109: 1300–1306.
40.
40 Truong D, Rontal M, Rolnick M, Aronson A, Mistura K. Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia. Laryngoscope1991; 101: 630–634.
41.
41 Brin MF, Blitzer A, Stewart CF, Diamond B, Pogoda JM. Botulinum toxin type A for adductor spasmodic dysphonia (laryngeal dystonia): double blind placebo controlled assessment of dose and technique. Neurology2001; 56(suppl 3): A346-A346.
42.
42 Wong DLH, Irish JC, Adams SG, Durkin LC, Hunt EJ. Laryngeal image analysis following botulinum toxin injections in spasmodic dysphonia. J Otolaryngol1995; 24: 64–68.
